Phase 3 Ovarian Cancer Trial, Recruiting NCT04878094 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 3 Ovarian Cancer Trial, Recruiting

NCT04878094
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been diagnosed with primary or recurring ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
  • People who are scheduled to have debulking or cytoreductive surgery (surgery to remove as much of the tumour as possible)
  • People where the surgical team suspects a section of the lower bowel (the rectosigmoid) may need to be removed during the debulking surgery
  • People who have agreed to take part and signed a consent form before the operation takes place
  • People who have had the rectosigmoid section of the bowel removed during surgery
  • People whose surgeon plans to reconnect the bowel (called a colorectal anastomosis) during the same operation

Who may not be able to join:

  • People who have had an allergic reaction to a dye called ICG (indocyanine green) in the past
  • People who were not asked to join the study before an unexpected lower bowel resection took place during surgery
  • People who did not end up having the lower bowel section removed during the operation
  • People whose lower bowel removal was related to a different type of gynaecological cancer (other than the cancers listed above)
  • People who require a permanent colostomy (a permanent opening in the abdomen for waste removal, rather than having the bowel reconnected)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Mario Leitao, MD, Memorial Sloan Kettering Cancer Center

Phone: 212-639-3987

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
3 May 2021
Est. completion
3 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Reduction of the risk of 30-day postoperative anastomotic leak at the site of rectosigmoid resection, compared with standard intraoperative assessment alone

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov